NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -4.8% ·
share flow +7.5% ·
net new positions -5.0%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 642.22K | $90.01M | n/a | −3 |
| Q2 2026 | 152 | 0 | 75.82M | $12.77B | +5 | −6 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 12.95M | n/a | $1.63B | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passive) | 9.81M | n/a | $1.23B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Dodge & Cox ✦ | 5.57M | +0.6% | $699.69M | 0.4% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 4.47M | -8.1% | $561.62M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 3.09M | +100.5% | $387.94M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 2.37M | -5.5% | $297.43M | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 2.05M | +130.5% | $257.55M | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 2.03M | -3.3% | $255.01M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 9 | Geode Capital Management ✦ (passive) | 1.96M | -0.5% | $245.57M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 1.51M | +40.5% | $189.79M | 0.2% | ▲ Add | 5 | SEC ↗ ×8 |
| 11 | Millennium Management ✦ | 1.19M | +107.1% | $150.10M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 972.86K | -2.7% | $122.28M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 524.04K | +37.0% | $65.87M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 341.58K | New | $42.93M | 0.1% | New | 1 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 254.84K | n/a | $32.03M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 16 | Arrowstreet Capital ✦ | 125.16K | +87.9% | $15.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 91.13K | +193.8% | $11.45M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 87.54K | -8.1% | $11.00M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Marshall Wace ✦ | 41.65K | New | $5.23M | 0.0% | New | 1 | SEC ↗ ×3 |
| 20 | Bridgewater Associates ✦ | 8.94K | -89.8% | $1.12M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $42.93M | 0.1% |
| Marshall Wace | $5.23M | 0.0% |
Exited
| Soros Fund Management | $26.52M | was 0.7% |
| D. E. Shaw & Co. | $1.61M | was 0.0% |
| Two Sigma Investments | $1.13M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 690 holders, 94.09M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 826 sh · $130,051
Officer · 2.31K sh · $363,285
Officer · 2.15K sh · $333,030
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology